 | Up a level |
Chen, Robert, Zinzani, Pier Luigi, Lee, Hun Ju, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Kim, Eunhee, Nahar, Akash, Balakumaran, Arun and Moskowitz, Craig H. (2019). Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood, 134 (14). S. 1144 - 1154. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Zinzani, Pier Luigi, Chen, Robert, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John 
ORCID: 0000-0001-7898-2786, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Nahar, Akash, Balakumaran, Arun and Moskowitz, Craig H.
(2020).
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis.
Leuk. Lymphoma, 61 (4).
S. 950 - 955.
ABINGDON:
TAYLOR & FRANCIS LTD.
ISSN 1029-2403